European regulators gave Boston Scientific (NYSE:BSX) the green light for its Guide 3D imaging system, touting it as the "world’s first" deep-brain stimulation visualization system.
The Guide device is designed to create a simulated 3D map of the brain’s electrical output, to help guide the placement of electrodes that deliver electrical pulses to the brain.
The Natick, Mass.-based medical device company said the Guide system is meant to be used alongside its Vercise DBS devices, which are both are approved in the EU for treating Parkinson’s disease.
“Guide DBS is a ground breaking technology,” Maulik Nanavaty, president of the neuromodulation division, said in a company press statement. “This innovative system is the first of its kind and designed to help physicians provide better therapy for their patients and improve programming time.”
Boston Scientific added to its DBS line in 2011 with the $78 million buyout of Intelect Medical.
